BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31703244)

  • 1.
    Orois A; Gara SK; Mora M; Halperin I; Martínez S; Alfayate R; Kebebew E; Oriola J
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31703244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
    Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
    Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
    Colombo C; Muzza M; Proverbio MC; Ercoli G; Perrino M; Cirello V; Vicentini L; Ferrero S; Fugazzola L
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):837-844. PubMed ID: 28222214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
    Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
    Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
    Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
    [No Abstract]   [Full Text] [Related]  

  • 7. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
    Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
    BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
    Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
    Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
    Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
    J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
    Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
    J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial non-medullary thyroid cancer: unraveling the genetic maze.
    Peiling Yang S; Ngeow J
    Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
    Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
    Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germ-line mutations in
    Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
    Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer.
    Orois A; Badenas C; Reverter JL; López V; Potrony M; Mora M; Halperin I; Oriola J
    Horm Cancer; 2020 Apr; 11(2):111-116. PubMed ID: 32172474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Novel Germline
    Hu Y; Han Z; Guo H; Zhang N; Shen N; Jiang Y; Huang T
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of
    Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
    Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
    [No Abstract]   [Full Text] [Related]  

  • 17. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families.
    Suh I; Filetti S; Vriens MR; Guerrero MA; Tumino S; Wong M; Shen WT; Kebebew E; Duh QY; Clark OH
    Surgery; 2009 Dec; 146(6):1073-80. PubMed ID: 19958934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
    Bauer AJ
    Front Horm Res; 2013; 41():141-8. PubMed ID: 23652675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
    Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
    Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on familial nonmedullary thyroid cancer.
    Ammar SA; Alobuia WM; Kebebew E
    Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.